KIORA PHARMACEUTICALS, INC. Deferred Revenue Recognized
KIORA PHARMACEUTICALS, INC. (KPRX) reported Deferred Revenue Recognized of $2.69 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2021-03-25
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $2.69M, a 2819.57% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2018-09-30 was $37.00K.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2018-06-30 was $137.00K.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was $92.00K.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for fiscal 2020 was $2.69M, a 0.00% change from fiscal 2019.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for fiscal 2019 was $2.69M, a 72.10% decline from fiscal 2018.
- KIORA PHARMACEUTICALS, INC. contract with customer, liability, revenue recognized for fiscal 2018 was $9.63M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2020-12-31 | $2.69M 10-K · filed 2021-03-25 | |||
| 2019-12-31 | $2.69M 10-K · filed 2020-03-04 | |||
| 2019-09-30 | $2.69M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $2.69M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $2.69M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $9.63M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $37.00K 10-Q · filed 2018-11-13 | $266.00K 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | $137.00K 10-Q · filed 2018-08-03 | $229.00K 10-Q · filed 2018-08-03 | ||
| 2018-03-31 | $92.00K 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |